- English
- Svenska

I-Tech announces outcome of warrant exercise

Publish date: 13 Jun 2025

I-Tech AB (publ) announces the successful exercise of warrants from the 2022/2025 series. The program included a total of 89,320 warrants, each allowing for the subscription of one share at a price of SEK 46.01 per share. All warrants were exercised, providing I-Tech with approximately SEK 4.1 million before issuance costs. As a result, the number of shares in I-Tech will increase by 89,320, from 11,908,457 to 11,997,777. Consequently, the share capital will increase by SEK 178,640, from SEK 23,816,914 to SEK 23,995,554.

DBCarnegie has assisted the company and the employees during the exercise with a cashless solution for the realization of the value in the program.

About I-Tech AB
I-Tech is a biotechnology company that has developed the antifouling technology Selektope®, an active substance that prevents barnacle attachment on submerged surfaces such as ships and boat hulls. By increasing the anti-barnacle performance in marine paint systems (e.g. antifouling coatings), fuel and maintenance costs are reduced ang vessel energy efficiency improved. I-Tech has obtained the necessary regulatory approvals for Selektope® and has several of the world’s largest manufacturers of marine antifouling coatings as customers. The company’s share is listed for trading on Nasdaq First North Growth Market in Stockholm. The Company’s Certified Adviser is DNB Carnegie Investment Bank AB. For more information visit our website www.i-tech.se.

Developers of Selektope®

I-Tech AB is a public held bio-technology company based in Mölndal, Sweden that owns all IP and regulatory rights to the antifouling agent Selektope® (generic name, medetomidine). I-Tech also controls the largest and most efficient source of medetomidine production.
Visit selektope.com

Contact information

info@i-tech.se
+46 10 30 33 999

I-Tech AB
Förändringens gata 10
SE-431 53 Mölndal, Sweden

I-Tech announces outcome of warrant exercise

Developers of Selektope®

Contact information

Navigate

Follow us